Introduction
============

Skin wound repair often results in the formation of scar tissue ([@b1-etm-0-0-7546]). Despite efforts, scars still cannot be avoided in clinical practice. Compared with skin, oral mucosa has the characteristics of quick healing and less scar tissue formation ([@b2-etm-0-0-7546]). Therefore, it is of great significance to study the factors of scar formation and the biological indicators in the process of skin wound repair. Wound repair is a complex process of interaction between cells, growth factors and extracellular matrices ([@b3-etm-0-0-7546]). Epidermal growth factor (EGF) is a heat-resistant single-chain polypeptide that can bind to cell membrane receptors and exert various biological effects ([@b4-etm-0-0-7546]). EGF, a potent mitogenic factor, promotes epithelial cell proliferation and division, improves collagen construction and regulates protein synthesis, thereby accelerating wound healing. EGF has chemotactic effects on vascular endothelial cells, fibroblasts, inflammatory cells and epidermal cells ([@b5-etm-0-0-7546]). Vascular endothelial growth factor C (VEGF-C) is a member separated from the vascular endothelial growth factor (VEGF)/platelet-derived factor (PDGF) family and is the fourth member of the VEGF subfamily. VEGF-C gene includes seven exons and is the largest VEGF gene currently described ([@b6-etm-0-0-7546]). Previous research has shown that high expression of VEGF-C plays an important role in the angiogenesis of limb ischemia in adult animals ([@b7-etm-0-0-7546]).

The moisture of oral mucosa is different from that of skin. Some scholars believe that the oral mucosa can be repaired with little or no scar because of the moisture and salivary protease ([@b8-etm-0-0-7546],[@b9-etm-0-0-7546]). In order to further clarify the factors in the process of scar formation and skin wound repair, the rat oral mucosa was transplanted to the right abdomen in this study. By comparing the differences in the expression of EGF and VEGF-C during skin healing, the role of the two factors in scar formation and skin wound repair was revealed.

Materials and methods
=====================

### Experimental animals

Sixty-four inbred strain SPF SD rats (150--190 g, 4--8 weeks) were purchased from Kaixue Biological Science and Technology (Shanghai) Co., Ltd. \[SCXK (Shanghai) 2009--0037; Shanghai, China\]. Rats were kept in a clean environment with good ventilation. The indoor humidity was 48--59%, and the temperature was 21--26°C. Rats were fed with SPF experimental rat food provided by Jiangsu Synergy Pharmaceutical Bioengineering Co., Ltd. (Jiangsu, China). Rats had free access to food and water.

The investigation was approved by the Ethics Committee of Jinan Maternity and Child Care Hospital (Jinan, China) and the experimental procedures were in compliance with the Guiding Principles for the Protection and Use of Experimental Animals ([@b10-etm-0-0-7546]). Patients who participated in this research had complete clinical data. Signed informed consents were obtained from the patients or the guardians.

### Animal model preparation

The 64 inbred strain SPF SD rats were randomly separated into group A, B, C and D (16 rats in each group) according to the principle of similar weight. Ten percent chloral hydrate were used for intraperitoneal injection anesthesia at a dose of 350 mg/kg. The abdomen of the rat faced up, and the limbs were immobilized. The right abdomen of the rat was first transplanted with oral mucosa. The full-thickness skin with a diameter of 1 cm of the right abdomen of the rat was cut. The skin was transplanted to the skin of the right abdomen and then sutured and bandaged. After that, rats were placed in a squirrel cage with free access to water and food. When the wound of the oral mucosa was healed for 14 days, intraperitoneal injection anesthesia was performed with the same dose of chloral hydrate, and then a full-thickness skin incision was made on the right abdomen of the rat with a round blade. The incision was deep to fascia layfer and was 1 cm in diameter. The same cut was made in the left abdomen of the rats and the wound diameter was 1 cm. Rats were allowed to reach food and water freely for a week. Rats in group A, B, C and D were anesthetized with chloral hydrate (350 mg/kg) and sacrificed by cervical dislocation 1, 3, 5 and 7 days after injury. Skin tissue with a diameter of about 1.5 cm around the center of the wound was collected. Skin tissue of the right abdomen was the study group, and the left abdomen skin tissue was the control group, being cryopreserved after collection.

### Indicator detection

Expression of EGF mRNA and VEGF-C mRNA in skin tissue were detected by RT-qPCR. Appropriate amount of tissue was washed twice with PBS, and the total RNA extraction of skin tissue was carried out in strict accordance with the instructions of TRIzol extraction kit (Shanghai Yusheng Biotechnology Co., Ltd., Shanghai, China). Absorbance of the RNA was measured using an ultraviolet-visible spectrophotometer (Mettler-Toledo International Trading Co., Ltd., Shanghai, China), and the concentration of RNA sample was calculated. One micrograms of RNA was reverse-transcribed into cDNA, and cDNA was prepared according to the instructions of M-MLV reverse transcription kit (Hanheng Biotechnology Co., Ltd., Shanghai, China). Reverse transcription reaction conditions: 42°C for 60 min and 85°C for 5 min, termination reaction at 4°C. Synthesized cDNA was stored at −20°C. Ten microliters of reaction system was prepared according to the instruction of Takara Real-Time PCR (Beijing Borma Biotechnology Co., Ltd., Beijing, China). Ten microliters of reaction system included 50 ng of total RNA, PCR Premix, double distilled water, ROX Dye and 200 nM primers. β-actin was used as an internal reference. Primer sequences are shown in [Table I](#tI-etm-0-0-7546){ref-type="table"}. Reaction procedure included 40 cycles of 95°C for 30 sec and 60°C for 33 sec. The experiment was repeated 3 times. Amplification data were analyzed by vendor software and the expression of EGF mRNA and VEGF-C mRNA was calculated by 2^−ΔCq^ method ([@b11-etm-0-0-7546]).

Expressions of EGF protein and VEGF-C protein in skin tissue were detected by ELISA. Appropriate amount of skin tissue was taken and washed in pre-cooled PBS (0.02 mol/l, pH 7.0--7.2) to remove blood, then crushed to prepare homogenate. The homogenate was centrifuged at 5,000 × g for 5 min at 4°C, and the supernatant was saved. EGF and VEGF-C ELISA assay kit (cat. nos. DEG00 and DVEC00; R&D Systems, Minneapolis, MN, USA) was used for the detection in accordance with the instructions. The sample and the kit was taken to room temperature 45 min in advance from the refrigerator, and the sample well, standard well and blank well were set. No reagents were added to the blank well. The sample well and the standard well were added with 50 µl of the sample to be tested and standard diluted in different multiples, respectively, with 50 µl of biotin-labeled antibody. The membrane was covered, and incubated at 37°C for 1 h. Liquid in each well was discarded, dried, and washed 3 times. Affinity streptavidin (80 µl) was added to each well, mixed and incubated at 37°C for 30 min. Liquid was discarded in each well, dried, and washed 3 times. Substrate A and B at 50 µl each, were added to the wells, mixed and incubated at 37°C for 10 min. A color change was produced in the dark at room temperature. Fifty microliters of the stop solution was added to each well, and the OD value of each well was measured at a wavelength of 450 nm using a 680 automatic microplate reader (Bio-Rad, Hercules, CA, USA) to calculate the expression levels of EGF and VEGF-C proteins.

### Statistical analysis

Statistical analysis was performed using SPSS 19.0 (IBM Corp., Armonk, NY, USA). Measurement data were expressed as mean ± standard deviation (mean ± SD). Chi-square test was used for the comparisons of inter-group count data. One-way ANOVA was used for the comparison of means among multiple groups. LSD-t-test was used for multiple comparisons between groups with LSD test as post hoc test. P\<0.05 indicates the difference is statistically significant.

Results
=======

### General condition of rats

One day after injury, wounds in the two groups began to heal. Wounds in the study group were smaller than those in the control group, and there were a small amount of granulation tissue on the wound surface. Three days after injury, wounds of the study group were significantly smaller than those of the control group, and the irregular granulation tissue was observed at the edge of the wound. Five days after injury, wounds of the two groups began to heal, and blood stasis was formed. The granulation tissue had shrunk, and the wound surface was closed. Seven days after injury, wound healing of the study group was better than that of the control group. Scar of the wound in the study group was better than that in the control group, and the wound surface was flatter compared with the control group. There were no differences in sex, age, length, blood glucose (Glu), body mass before and after modeling, indoor temperature and indoor humidity among group A, B, C and D ([Table II](#tII-etm-0-0-7546){ref-type="table"}).

### Expressions of EGF mRNA and protein at different time-points in rats

Expressions of EGF mRNA and protein in the skin tissue of the study group were not significantly different from that of the control group at 1 and 3 days (P\>0.05). At 3 days, expression levels of EGF mRNA and protein in skin tissue of the two groups were significantly higher than those at 1 day (P\<0.05). At 5 days, expression levels of EGF mRNA and protein in skin tissue of the two groups were significantly higher than those at 3 days (P\<0.05), and the expression levels of EGF mRNA and protein in skin tissue of the study group were significantly higher than those of the control group (P\<0.05). At 7 days, expression levels of EGF mRNA and protein in skin tissue of the two groups were significantly lower than those at 5 days (P\<0.05) and the expression levels of EGF mRNA and protein in skin tissue of the study group were significantly lower than those of the control group (P\<0.05) ([Tables III](#tIII-etm-0-0-7546){ref-type="table"} and [IV](#tIV-etm-0-0-7546){ref-type="table"} and [Fig. 1](#f1-etm-0-0-7546){ref-type="fig"}).

### Expression of VEGF-C mRNA and protein at different time-points in rats

Expression levels of VEGF-C mRNA and protein in skin tissue of the study group were not significantly different from those of the control group at 1 day (P\>0.05). At 3 and 5 days, expression levels of VEGF-C mRNA and protein in the skin tissue of the study group were significantly higher than those of the control group. At 3 days, expression levels of VEGF-C mRNA and protein in skin tissue of the two groups were significantly higher than those at 1 day (P\<0.05). At 5 days, expression levels of VEGF-C mRNA and protein in skin tissue of the two groups were significantly higher than those at 3 days (P\<0.05). At 7 days, expression levels of VEGF-C mRNA and protein in skin tissue of the two groups were significantly higher than those at 5 days (P\<0.05) and the expression levels of VEGF-C mRNA and protein in skin tissue of the study group were significantly lower than those of the control group (P\<0.05) ([Tables V](#tV-etm-0-0-7546){ref-type="table"} and [VI](#tVI-etm-0-0-7546){ref-type="table"} and [Fig. 2](#f2-etm-0-0-7546){ref-type="fig"}).

Discussion
==========

Scar formed after wound healing is a clinical problem. The requirements for the prognosis of wounds are getting higher, and scar-free wound repair is expected. Therefore, the scar healing after wound healing has become a research hotspot for scholars ([@b12-etm-0-0-7546],[@b13-etm-0-0-7546]). Healing process of oral mucosa is rapid, with few scars. Therefore, oral mucosal healing is of importance in the deeper understanding of skin wound repair ([@b14-etm-0-0-7546],[@b15-etm-0-0-7546]). This study transplanted the rat tongue mucosa to the right abdomen skin, made a full-thickness skin wound and observed biological indicators that may become factors of scar formation, providing a theoretical basis for scar wound healing.

When the body is damaged, cells and tissues at the wound site will secrete a large number of wound healing growth factors. Growth factors are cytokines that stimulate cell growth activity and play an important role in the body wound repair process ([@b16-etm-0-0-7546]). Cytokines can attract fibroblasts and inflammatory cells into the wound, which promotes vascularization and cell proliferation of the wound ([@b17-etm-0-0-7546]). EGF is a novel type of polypeptide factor found in the purification of mouse submandibular gland nerve growth factor. It is a biologically active substance that stimulates cell proliferation and is widely distributed in tissues and body fluids ([@b18-etm-0-0-7546],[@b19-etm-0-0-7546]). EGF may be one of the most characterized growth factors in the process of skin wound healing. In acute trauma, EGF is mainly secreted by platelets, macrophages and fibroblasts, and is upregulated in a short time after injury ([@b20-etm-0-0-7546],[@b21-etm-0-0-7546]). Release of EGF stimulates migration and proliferation of epithelial cells, thereby promoting re-epithelialization ([@b22-etm-0-0-7546]). Kim *et al* ([@b23-etm-0-0-7546]) found that EGF can reduce the expression of TGF-β, reduce skin scars, and mediate collagen formation by inhibiting inflammatory response. During the process of lymphangiogenesis, it can be stimulated by various cytokines, including VEGF-C. VEGF-C is the first identified ligand of growth factor receptor 3 (Flt4) and is a member of the polypeptide growth factor family ([@b24-etm-0-0-7546],[@b25-etm-0-0-7546]). It has been shown that overexpressed VEGF-C cDNA in the skin of transgenic mice can induce lymphatic endothelial cell proliferation and lymphangiogenesis, recombinant VEGF-C and can specifically stimulate lymphangiogenesis in the chorioallantoic membrane ([@b26-etm-0-0-7546]). Results of this study showed that expression levels of EGF and VEGF-C mRNA and protein in skin tissue of the two groups were significantly higher at 3 days than at 1 day; expression levels of EGF and VEGF-C mRNA and protein in skin tissue of the two groups were significantly higher at 5 days than at 3 days; expression levels of EGF mRNA and protein in skin tissue of the two groups were significantly lower at 7 days than at 5 days, while expression levels of VEGF-C mRNA and protein were significantly higher at 7 days than at 5 days. It is suggested that EGF and VEGF-C may be involved in scar formation. Irregular granulation tissue appeared on the 3rd day after injury, and blood stasis formed on the 5th day. Hyperplasia of rat skin repair tissue cells and wound healing began from this stage. In this study, expression levels of VEGF-C mRNA and protein in skin tissue of the study group were significantly higher than those of the control group at 3 days. Expression levels of EGF and VEGF-C mRNA and protein in skin tissue of the study group were significantly higher than those of the control group at 5 days. At 7 days, expression levels of EGF and VEGF-C mRNA and protein in skin tissue of the study group were significantly lower than those of the control group. It is suggested that oral mucosal transplantation has the characteristics of quick repair and good effect in skin wound repair. EGF and VEGF-C may play an important role in skin wound repair.

Previous studies have shown that exogenous growth factors can promote scar-free healing of wounds. However, the separation of growth factors remains to be studied, because the level of growth factor is low in the body. Determination of appropriate concentration of growth factor and the regulation of it to interfere with cell proliferation is of great significance for wound healing to reduce scar formation, which will be the focus of our future study.

In summary, EGF and VEGF-C may be involved in scar formation and play an important role in the process of skin wound repair.
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###### 

Primers of EGF mRNA, VEGF-C mRNA and β-actin.

  Gene      Forward primers                Reverse primers
  --------- ------------------------------ ------------------------------
  EGF       5′-TGCCAACTGGGGGTGCACAG-3′     5′-CTGCCCGTGGCCAGCGTGGC-3′
  VEGF-C    5′-TTCCATTATTAGACGTTCCCTG-3′   5′-GTGTTTTCATCAAATTCTCGGT-3′
  β-actin   5′-AAATCGTGCGTGACATTAA-3′      5′-CTCGTCATACTCCTGCTTG-3′

EGF, epidermal growth factor; VEGF-C, vascular endothelial growth factor C.

###### 

General condition of rats \[n (%)\] (mean ± SD).

  Items                           A (n=16)       B (n=16)       C (n=16)      D (n=16)       F/χ2    P-value
  ------------------------------- -------------- -------------- ------------- -------------- ------- ---------
  Sex                                                                                        4.726   0.193
    Male                          11 (68.75)     9 (56.25)      14 (87.50)    13 (81.25)             
    Female                          5 (31.25)    7 (43.75)        2 (12.50)     3 (18.75)            
  Age (weeks)                     8.41±0.27      8.32±0.41      8.59±0.49     8.26±0.38      2.118   0.107
  Length (cm)                     18.45±1.42     19.41±0.82     18.91±1.57    18.45±1.19     2.043   0.117
  Glu (mmol/l)                    73.48±4.27     70.78±4.53     69.24±5.76    71.13±5.34     1.957   0.130
  Body mass before modeling (g)   221.54±12.35   227.12±14.24   218.36±9.87   216.63±11.58   2.319   0.085
  Body mass after modeling (g)    212.63±7.57    208.53±7.41    206.47±7.82   209.47±8.63    1.697   0.177
  Indoor temperature (°C)         24.05±1.24     23.78±1.08     24.25±0.93    24.16±0.57     0.682   0.566
  Indoor humidity (%)             51.52±2.63     50.74±1.93     50.71±1.35    49.93±1.07     1.982   0.126

###### 

Expression of EGF mRNA at different time-points in rats (mean ± SD).

  Groups    1 day (n=16)   3 days (n=16)                                             5 days (n=16)                                              7 days (n=16)                                             F-value   P-value
  --------- -------------- --------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- --------- ---------
  Study     3.56±0.43      8.43±0.76^[a](#tfn2-etm-0-0-7546){ref-type="table-fn"}^   16.63±1.25^[b](#tfn3-etm-0-0-7546){ref-type="table-fn"}^   7.93±0.97^[c](#tfn4-etm-0-0-7546){ref-type="table-fn"}^   582.700   \<0.001
  Control   3.37±0.38      8.63±0.83^[a](#tfn2-etm-0-0-7546){ref-type="table-fn"}^   11.67±1.77^[b](#tfn3-etm-0-0-7546){ref-type="table-fn"}^   9.46±1.56^[c](#tfn4-etm-0-0-7546){ref-type="table-fn"}^   123.700   \<0.001
  t-value   0.489          0.515                                                     12.760                                                     3.937                                                               
  P-value   0.626          0.608                                                     \<0.001                                                    \<0.001                                                             

P\<0.05, compared to 1st day

P\<0.05, compared to 3rd day

P\<0.05, compared to 5th day. EGF, epidermal growth factor.

###### 

Expression of EGF protein at different time-points in rats (ng/ml) (mean ± SD).

  Groups    1 day (n=16)   3 days (n=16)                                             5 days (n=16)                                              7 days (n=16)                                             F-value    P-value
  --------- -------------- --------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------- ---------- ---------
  Study     3.95±0.71      5.46±0.94^[a](#tfn5-etm-0-0-7546){ref-type="table-fn"}^   12.26±1.07^[b](#tfn6-etm-0-0-7546){ref-type="table-fn"}^   6.85±1.26^[c](#tfn7-etm-0-0-7546){ref-type="table-fn"}^   203.500    \<0.001
  Control   3.85±0.69      5.71±1.03^[a](#tfn5-etm-0-0-7546){ref-type="table-fn"}^   10.57±1.53^[b](#tfn6-etm-0-0-7546){ref-type="table-fn"}^   8.69±1.46^[c](#tfn7-etm-0-0-7546){ref-type="table-fn"}^     95.920   \<0.001
  t-value   0.251          0.628                                                     4.248                                                      4.625                                                                
  P-value   0.802          0.531                                                     \<0.001                                                    \<0.001                                                              

P\<0.05, compared to 1st day

P\<0.05, compared to 3rd day

P\<0.05, compared to 5th day. EGF, epidermal growth factor.

###### 

Expression levels of VEGF-C mRNA at different time-points in rats (mean ± SD).

  Groups    1 day (n=16)   3 days (n=16)                                             5 days (n=16)                                              7 days (n=16)                                               F-value   P-value
  --------- -------------- --------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- --------- ---------
  Study     4.47±0.86      7.58±0.93^[a](#tfn8-etm-0-0-7546){ref-type="table-fn"}^   10.47±1.57^[b](#tfn9-etm-0-0-7546){ref-type="table-fn"}^   11.63±1.47^[c](#tfn10-etm-0-0-7546){ref-type="table-fn"}^   105.300   \<0.001
  Control   4.38±0.72      6.19±0.95^[a](#tfn8-etm-0-0-7546){ref-type="table-fn"}^   8.67±1.24^[b](#tfn9-etm-0-0-7546){ref-type="table-fn"}^    13.76±1.85^[c](#tfn10-etm-0-0-7546){ref-type="table-fn"}^   166.400   \<0.001
  t-value   0.203          3.131                                                     4.055                                                      4.798                                                                 
  P-value   0.840          0.002                                                     \<0.001                                                    \<0.001                                                               

P\<0.05, compared to 1st day

P\<0.05, compared to 3rd day

P\<0.05, compared to 5th day. VEGF-C, vascular endothelial growth factor C.

###### 

Expression levels of VEGF-C protein (ng/ml) at different time-points in rats (mean ± SD).

  Groups    1 day (n=16)   3 days (n=16)                                              5 days (n=16)                                              7 days (n=16)                                              F-value   P-value
  --------- -------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- --------- ---------
  Study     2.53±0.21      3.87±0.59^[a](#tfn11-etm-0-0-7546){ref-type="table-fn"}^   5.08±0.47^[b](#tfn12-etm-0-0-7546){ref-type="table-fn"}^   5.97±0.61^[c](#tfn13-etm-0-0-7546){ref-type="table-fn"}^   145.100   \<0.001
  Control   2.46±0.26      3.19±0.41^[a](#tfn11-etm-0-0-7546){ref-type="table-fn"}^   4.17±0.53^[b](#tfn12-etm-0-0-7546){ref-type="table-fn"}^   6.75±0.64^[c](#tfn13-etm-0-0-7546){ref-type="table-fn"}^   242.700   \<0.001
  t-value   0.405          3.935                                                      5.266                                                      4.513                                                                
  P-value   0.686          \<0.001                                                    \<0.001                                                    \<0.001                                                              

P\<0.05, compared to 1st day

P\<0.05, compared to 3rd day

P\<0.05, compared to 5th day. VEGF-C, vascular endothelial growth factor C.
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